PARADIGM BIOCAPITAL ADVISORS LP
Q1 2025 Form 13-F
NEW YORK, NEW YORK
CIK 0001855655
· CRD 312544
· SEC-registered investment adviser
$2.2B Reported Value Total
PARADIGM BIOCAPITAL ADVISORS LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $3,054,844,396, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $4.1B gross asset value
Hedge Fund: $4.1B
Source: Form ADV filed 2026-08-27
Reported value
$2.2B
Quarter over quarter
-17.3%
Holdings
27
Top-10 concentration
76.0%
Key People
Form ADV owners & control persons
Dr. Senai Nmn Asefaw
CHIEF INVESTMENT OFFICER / LIMITED PARTNER
David Kyungtaek Kim
CHIEF OPERATING OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 15, 2025 |
| Form | 13F-HR |
| Reported value | $2.2B |
| Positions | 27 |
| Change in reported value | -24.0% |
| New positions | 5 |
| Exited positions | 6 |
| Position turnover | 33.3% |
| Top-10 concentration | 76.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
28 | $5.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
35 | $4.9B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $3.9B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
33 | $3.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
28 | $2.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
27 | $2.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $2.9B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
31 | $3.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $2.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
34 | $2.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
29 | $1.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
29 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
25 | $1.1B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
23 | $851.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
27 | $750.1M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
23 | $501.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
25 | $378.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
24 | $350.2M |
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NUVL NUVALENT INC | $373.7M | 17.12% |
| 2 | ACLX ARCELLX INC | $294.7M | 13.5% |
| 3 | RVMD REVOLUTION MEDICINES INC | $218.5M | 10.01% |
| 4 | ONC BEIGENE LTD | $181.3M | 8.3% |
| 5 | MRUS MERUS N V | $141.8M | 6.5% |
| 6 | TARS TARSUS PHARMACEUTICALS INC | $134.1M | 6.14% |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | $96.7M | 4.43% |
| 8 | JANX JANUX THERAPEUTICS INC | $89.9M | 4.12% |
| 9 | CRNX CRINETICS PHARMACEUTICALS IN | $65.3M | 2.99% |
| 10 | PCVX VAXCYTE INC | $64.1M | 2.93% |
| 11 | IRON DISC MEDICINE INC | $60.1M | 2.75% |
| 12 | COGT COGENT BIOSCIENCES INC | $53.7M | 2.46% |
| 13 | LENZ LENZ THERAPEUTICS INC | $38.9M | 1.78% |
| 14 | APGE APOGEE THERAPEUTICS INC | $35.9M | 1.65% |
| 15 | ARGX ARGENX SE | $35.3M | 1.62% |
| 16 | CYTK CYTOKINETICS INC | $34.5M | 1.58% |
| 17 | INSM INSMED INC | $34.4M | 1.58% |
| 18 | SYRE SPYRE THERAPEUTICS INC | $34.3M | 1.57% |
| 19 | MTSR METSERA INC | $32.4M | 1.49% |
| 20 | VRDN VIRIDIAN THERAPEUTICS INC | $28.2M | 1.29% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.